Advanced search
Publication Cover
Cancer Biology & Therapy Volume 25, 2024 - Issue 1
Submit an article Journal homepage
1,551
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer

Zhideng Yana Department of General Surgery, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, ChinaView further author information
,
Zhihui Zhongb Center of Stem Cell and Regenerative Medicine, Gaozhou People’s Hospital, Gaozhou, Guangdong, ChinaView further author information
,
Chuanke Shia Department of General Surgery, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, ChinaView further author information
,
Muyin Fengc Department of Pathology, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, ChinaView further author information
,
Xiaoqiang Fengb Center of Stem Cell and Regenerative Medicine, Gaozhou People’s Hospital, Gaozhou, Guangdong, ChinaCorrespondence[email protected]
View further author information
&
Tong Liua Department of General Surgery, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0000-8659-1662View further author information
ORCID Icon
Article: 2355705 | Received 22 Feb 2024, Accepted 11 May 2024, Published online: 22 May 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.